Loading
Neuroendocrine Tumor Research Advances / Diabetes Treatment and Management · Journal article
PLOS One · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a study protocol—not a completed trial—describing a planned retrospective cohort investigation of GLP-1 receptor agonist use in patients with intraductal papillary mucinous neoplasms across three Swiss centres. The study is designed to generate preliminary data on IPMN progression and safety signals, not to provide definitive evidence; the authors acknowledge the expected small sample size and retrospective design will limit statistical power.
Retrospective multicentric cohort study with 2×2 stratification. Patients with radiological diagnosis of IPMN and/or treated with GLP-1 RAs at three Swiss tertiary institutions; eligibility criteria fully detailed in protocol manuscript (not provided in this source text).. Intervention: GLP-1 receptor agonist use (observational exposure). Compared with: No GLP-1 RA use (stratified comparator group). Three Swiss tertiary institutions.
This is a study protocol—not a completed trial—describing a planned retrospective cohort investigation of GLP-1 receptor agonist use in patients with intraductal papillary mucinous neoplasms across three Swiss centres. The study is designed to generate preliminary data on IPMN progression and safety signals, not to provide definitive evidence; the authors acknowledge the expected small sample size and retrospective design will limit statistical power.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This protocol does not yet provide clinical evidence. When results are published, they may help identify safety signals or trends regarding GLP-1 RA use in patients with pancreatic cystic neoplasms, but the small anticipated sample and retrospective design mean findings will require confirmation in larger studies before informing clinical practice.
This is a protocol for a retrospective cohort study with an acknowledged small sample size (30–60 patients) and retrospective design; it is designed to generate preliminary data and hypotheses rather than definitive evidence, and no results are yet reported.
As stated by the source record.
Quoted from the source exactly as published.
This protocol does not yet provide clinical evidence. When results are published, they may help identify safety signals or trends regarding GLP-1 RA use in patients with pancreatic cystic neoplasms, but the small anticipated sample and retrospective design mean findings will require confirmation in larger studies before informing clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Aim of the study Intraductal papillary mucinous neoplasms (IPMNs) are among the most common cystic pancreatic neoplasms, with a potential to progress to malignancy. The increasing prevalence of IPMNs, coupled with the widespread use of GLP-1 receptor agonists (GLP-1 RAs) for diabetes and obesity management, raises concerns about the safety of these medications in patients with preexisting pancreatic conditions. Despite their proven metabolic benefits, questions remain about their impact on pancreatic pathology. This study investigates the association between GLP-1 RA use and IPMN progression to address this critical gap in the current literature. Methods This retrospective multicentric cohort study will analyse data from January 2010 to July 2026 across three Swiss tertiary institutions. Patients with a radiological diagnosis of IPMN and/or treated with GLP-1 RAs will be included. Patients will be stratified into four groups according to a 2 × 2 design based on GLP-1 RAs exposure and IPMN status. The primary objective is to evaluate the impact of GLP-1 RAs on IPMN progression using radiological criteria from the Kyoto 2023 Consensus. Secondary objectives include assessing changes in tumour markers (CA19−9, CEA), the incidence of acute pancreatitis, the progression of IPMNs to high-grade dysplasia or invasive carcinoma, and the need for surgical intervention or altered surveillance protocols associated with GLP1 RAs use. Discussion This study aims to explore potential associations between GLP-1 RA use and changes in IPMN characteristics, tumour markers, and disease progression. Given the retrospective design and expected small sample size (estimated at 30–60 patients in total), the study may not be powered to establish definitive correlations. Nonetheless, it will generate preliminary data to help inform hypotheses and guide future research. Any observed trends could provide valuable insights into the safety of GLP-1 RAs in patients with IPMNs and contribute to more informed clinical decision-making regarding the use of these agents in a population at risk for pancreatic disease progression. Trial registration ClinicalTrials.gov NCT07014709
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.